MARKET

IDXG

IDXG

Interpace Biosciences Inc
OTCQX

Real-time Quotes | Nasdaq Last Sale

3.540
+0.390
+12.38%
Closed 14:16 05/17 EDT
OPEN
3.290
PREV CLOSE
3.150
HIGH
3.550
LOW
3.290
VOLUME
1.70K
TURNOVER
5.99K
52 WEEK HIGH
10.51
52 WEEK LOW
2.930
MARKET CAP
14.85M
P/E (TTM)
-0.7216
1D
5D
1M
3M
1Y
5Y
Interpace Biosciences GAAP EPS of -$0.53, revenue of $10.38M
Interpace Biosciences press release (OTCQX:IDXG): Q1 GAAP EPS of -$0.53. Revenue of $10.38M (+5.6% Y/Y). March 31, 2022 cash balance was $2.9 million, net of restricted cash and May 12,
Seekingalpha · 1d ago
Interpace Biosciences Announces First Quarter 2022 Financial and Business Results
●Q1 Revenue of $10.4 million up 6% versus Prior Year ●Q1 Net Loss improved $2 million versus Prior Year ●Days Sales Outstanding (DSO) decreased by 27% PARSIPPANY, NJ, May 16, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company...
GlobeNewswire · 1d ago
-- Earnings Flash (IDXG) INTERPACE BIOSCIENCES Posts Q1 Revenue $10.4M
MT Newswires · 1d ago
Miroculus to Optimize Automated Next Generation Sequencing Library Preparation with Interpace Diagnostics and Twist Bioscience
PARSIPPANY, NJ, May 11, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, has announced that in association with Miroculus, Inc., a developer of revolutionary tool...
GlobeNewswire · 6d ago
Interpace Biosciences GAAP EPS of -$0.89, revenue of $10.86M
Interpace Biosciences press release (OTCQX:IDXG): Q4 GAAP EPS of -$0.89. Revenue of $10.86M (+12.5% Y/Y).
Seekingalpha · 03/31 20:52
Interpace Biosciences Announces Full Year and Fourth Quarter 2021 Financial and Business Results
●2021 Full Year Net Revenue of $41.3 Million up 28% vs Prior Year; Fourth Quarter Net Revenue of $10.9 Million up 13% vs Prior Year ●2021 Full Year Net Loss Improved $11.5 Million vs Prior Year ●Full year Cash Collections improved by 31% to $43.1 million a...
GlobeNewswire · 03/31 20:15
-- Earnings Flash (IDXG) INTERPACE BIOSCIENCES Posts Q4 Revenue $10.9M
MT Newswires · 03/31 16:26
Interpace Biosciences Announces Update of Previously Announced CMS Billing Policy Impacting its Thyroid Tests
PARSIPPANY, NJ, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, announced today that the National Correct Coding Initiative (NCCI) program issued a resp...
GlobeNewswire · 02/22 14:00
More
No Data
Learn about the latest financial forecast of IDXG. Analyze the recent business situations of Interpace Biosciences Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average IDXG stock price target is 11.00 with a high estimate of 11.00 and a low estimate of 11.00.
High11.00
Average11.00
Low11.00
Current 3.540
EPS
Actual
Estimate
-1.14-0.86-0.57-0.29
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 30
Institutional Holdings: 1.18M
% Owned: 28.01%
Shares Outstanding: 4.20M
TypeInstitutionsShares
Increased
1
11.58K
New
7
-428.38K
Decreased
2
4.94K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Managed Healthcare
+0.72%
Healthcare Providers & Services
+1.07%
Key Executives
President/Chief Executive Officer/Director
Thomas Burnell
Chief Financial Officer/Treasurer/Secretary
Thomas Freeburg
Director
Vijay Aggarwal
Director
Robert Gorman
Independent Director
Edward Chan
Independent Director
Joseph Keegan
Independent Director
Fortunato Rocca
Independent Director
Stephen Sullivan
No Data
No Data
About IDXG
Interpace Biosciences, Inc., formerly Interpace Diagnostics Group, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, it provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.

Webull offers kinds of Interpace Biosciences Inc stock information, including OTCQX:IDXG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IDXG stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IDXG stock methods without spending real money on the virtual paper trading platform.